Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Advances in lung cancer].

P Pautier1

  • 1Service d'Oncologie Moléculaire, Pavillon de Recherche n. 1, Institut Gustave Roussy, Villejuif, France.

Pathologie-Biologie
|December 1, 1992
PubMed
Summary
This summary is machine-generated.

The 28th ASCO meeting highlighted non-small cell lung cancer (NSCLC) staging and neoadjuvant therapy. New chemotherapy drugs show promise for improving NSCLC treatment outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinico-molecular predictors of durable response to immune checkpoint inhibitors (ICI) in metastatic cervical cancer (mCC).

British journal of cancer·2026
Same author

Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.

Gynecologic oncology·2024
Same author

Targeting the immune microenvironment in ovarian cancer therapy-mission impossible?

ESMO open·2024
Same author

Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Breast Cancer Patients' Experience and Wishes Regarding Communication on Sexual Health: The BEROSE Study.

Cancer investigation·2022
Same author

Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials.

ESMO open·2022

Area of Science:

  • Oncology
  • Pulmonology
  • Medical Oncology

Background:

  • The 28th annual meeting of the American Society of Clinical Oncology (ASCO) focused on lung cancer, particularly non-small cell lung cancer (NSCLC).
  • Accurate staging is crucial for NSCLC prognosis, especially in Stage IIIA, where resection outcomes vary based on tumor and nodal involvement (T3N0, T3N1 vs. N2).

Purpose of the Study:

  • To review key advancements in lung cancer treatment discussed at the 28th ASCO meeting.
  • To highlight progress in staging, neoadjuvant therapy, and novel chemotherapeutic agents for NSCLC.
  • To summarize therapeutic strategies explored for small cell lung cancer (SCLC).

Main Methods:

  • Discussion of findings presented at the 28th ASCO annual meeting.
  • Review of therapeutic approaches for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Related Experiment Videos

  • Focus on advancements in staging systems, neoadjuvant therapy, and new drug development for NSCLC.

    • Main Results:

    • Emphasis on the critical role of accurate staging, particularly for Stage IIIA NSCLC, impacting prognostic factors after resection.
    • Exploration of neoadjuvant therapy as a key treatment strategy for Stage IIIA NSCLC.
    • Introduction of novel chemotherapy agents (Navelbine, Taxol, Campthotecine) indicating potential improvements in NSCLC treatment.

    Conclusions:

    • The 28th ASCO meeting underscored the importance of precise staging and neoadjuvant therapy for NSCLC.
    • Emerging chemotherapeutic agents offer promising avenues for enhancing NSCLC treatment efficacy.
    • Ongoing trials for SCLC focus on optimizing dose intensity and transplantation methods.